<DOC>
	<DOCNO>NCT00047723</DOCNO>
	<brief_summary>The purpose trial test safety , tolerability , effectiveness minocycline compare placebo patient amyotrophic lateral sclerosis ( ALS ) .</brief_summary>
	<brief_title>Minocycline Treat Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>ALS progressive neurodegenerative disorder without cure know treatment significantly improve function . Loss motor neuron brain spinal cord ALS patient cause progressive symptom . Laboratory study link inducible nitric oxide synthase ( iNOS ) caspase enzyme activation motor nerve cell death ALS . Minocycline-a medication currently approve FDA treatment bacterial infections-is tetracycline antibiotic high central nervous system penetration take orally . The drug inhibit activity iNOS caspase enzyme . Minocycline test show protect nerve cell many scientific experiment . It reduce cell death prolongs survival animal model ALS , stroke , trauma , Huntington 's disease , Parkinson 's disease . It show beneficial many different animal experiment ALS , conduct Europe , Canada United States . Minocycline test 2 preliminary human trial show safe patient ALS . It well tolerate conjunction riluzole ( Rilutek ) , currently FDA-approved medication ALS . This trial final important step determine whether minocycline improves course ALS . The principle objective clinical trial determine whether minocycline slow disease progression help maintain function patient ALS . This multi-center placebo-controlled study select patient early course ALS , neuroprotective therapy may beneficial . The study measure change function ( detected ALSFRS-R score ) , strength , pulmonary function , survival , quality life . Participants undergo monthly outpatient evaluation analysis laboratory adverse event . This 13-month study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>To eligible enrollment study , subject must meet following eligibility criterion within fourteen day prior randomization : Inclusion criterion : A clinical diagnosis laboratorysupported probable , probable definite ALS , accord modify EL Escorial criterion . FVC great equal 75 % predict . Onset weakness within 3 year prior enrollment . If patient receive riluzole must stable dose least past thirty day . Women childbearing age must nonlactating surgically sterile use effective method birth control negative pregnancy test ( adequate birth control include use intrauterine device oral contraceptive plus barrier method , e.g . condom , diaphragm ) . Willing able give sign informed consent approve Institutional Review Board ( IRB ) . Exclusion criterion : Requirement tracheotomy ventilation ( noninvasive ventilation &gt; 23 hours/day ) . Diagnosis neurodegenerative disease ( Parkinson 's disease , Alzheimer 's disease , etc ) . FVC &lt; 75 % predict . A clinically significant history unstable medical illness ( unstable angina , advanced cancer , etc ) last 30 day . History renal disease ( screen creatinine great 1.5 ) . History liver disease ( screen alanine aminotransferase great 3 time upper limit normal ) . History hematologic disease ( screen white blood cell count le 3,800/mm3 ) . History system lupus erythematosis ( screen ANA 1:160 great ) . Treatment medication may cause lupuslike symptom within 4 week baseline visit ( e.g . procainamide , hydralazine ) . History vestibular disease ( exclude benign position vertigo ) . Pregnancy lactation . Allergy tetracycline antibiotic . Use minocycline within thirty day enrollment ( baseline visit ) . Use antiepileptic medication gabapentin . Limited mental capacity render subject unable provide write informed consent comply evaluation procedure . History recent alcohol drug abuse noncompliance treatment experimental protocol . Use investigational drug within past 30 day ( Creatine , Vioxx , Celebrex , Topiramate ) . Women potential become pregnant practice effective birth control .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>ALS</keyword>
	<keyword>amyotrophic lateral sclerosis</keyword>
	<keyword>minocycline</keyword>
</DOC>